Prof. Tanya Gurevich, M.D, presents at the International Congress of Parkinson’s Disease and Movement Disorders®, October 2025. 

5-9 October 2025

Prof. Tanya Gurevich, M.D presented interim results of the ongoing Phase 1 clinical study with human oral mucosa neural crest stem cells (hOMSC300) intrathecally administrated to moderate and advanced Multiple System Atrophy (MSA) patients, at the International Congress of Parkinson's Disease and Movement Disorders® in Honolulu, Hawaii October 5-9, 2025.

​

This first-in-human, open label, single center, Phase 1 study is evaluating the safety of hOMSC300 following intrathecal administration in patients with moderate or advanced stages of MSA with
18 months follow-up. The interim safety data demonstrated that intrathecal administration was safe, with no serious adverse events (SAEs) related to hOMSC300 occurred during this period. Additionally, there was no significant disease progression up to 9 months post injection.